Trump's tariffs will not only impact sponsors, but higher costs will ripple down the clinical trial supply chain in the US.

The following stocks are all recommended by Argus analysts and have a "positive" Thomson Reuters consensus rating and a "long" Market Edge rating: State Street is one of the world's largest custody ...

Foreign participants at the 16th Asia Pharma Expo foresee a bright future for Bangladesh’s pharmaceutical industry, given its ...

With a 10% tariff making Chinese products costlier, US importers may turn to Indian companies as cost-effective alternatives.

GlobalData’s Revati Tatake discussed key trends in biopharma which are set to have an impact in 2025 and beyond.

A new survey from the ABPI has revealed a surge in apprenticeships, placements and global research collaborations in the UK ...

DMU will be part of a consortium laying the foundation for future medicines that are affordable, safe, effective, and ...

The importance of a strategic approach and proper due diligence in unlocking the full potential of these arrangements.

Today, adoption of digital health faces some of the same barriers — scepticism, budget limitations, high expectations, and a ...

Hyundai Motor India Ltd. is the only large-cap Indian stock that has been added to the MSCI Global Standard Indexes in the latest review, while Adani Green Energy shares have been deleted from the ...

The US exit from the World Health Organisation (WHO) creates a funding gap but also opens doors for India to lead in global ...